Logo image of LUCD

LUCID DIAGNOSTICS INC (LUCD) Stock Price, Quote, News and Overview

NASDAQ:LUCD - Nasdaq - US54948X1090 - Common Stock - Currency: USD

1.12  -0.02 (-1.75%)

Premarket: 1.16 +0.04 (+3.57%)

LUCD Quote, Performance and Key Statistics

LUCID DIAGNOSTICS INC

NASDAQ:LUCD (7/18/2025, 8:00:01 PM)

Premarket: 1.16 +0.04 (+3.57%)

1.12

-0.02 (-1.75%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
Statistics
52 Week High1.8
52 Week Low0.72
Market Cap121.17M
Shares108.19M
Float70.82M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11/bmo
IPO10-14 2021-10-14


LUCD short term performance overview.The bars show the price performance of LUCD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

LUCD long term performance overview.The bars show the price performance of LUCD in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60

The current stock price of LUCD is 1.12 USD. In the past month the price decreased by -11.11%. In the past year, price increased by 33.37%.

LUCID DIAGNOSTICS INC / LUCD Daily stock chart

LUCD Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.24 215.17B
ISRG INTUITIVE SURGICAL INC 67.88 185.88B
BSX BOSTON SCIENTIFIC CORP 38.39 153.33B
SYK STRYKER CORP 31.08 148.81B
MDT MEDTRONIC PLC 16.29 114.81B
BDX BECTON DICKINSON AND CO 12.69 51.26B
EW EDWARDS LIFESCIENCES CORP 29.42 44.87B
IDXX IDEXX LABORATORIES INC 45.14 41.38B
RMD RESMED INC 28.41 37.82B
GEHC GE HEALTHCARE TECHNOLOGY 16.51 34.78B
DXCM DEXCOM INC 50.84 32.89B
PHG KONINKLIJKE PHILIPS NVR- NY 15.38 23.69B

About LUCD

Company Profile

LUCD logo image Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. The company is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.

Company Info

LUCID DIAGNOSTICS INC

360 Madison Avenue, 25th Floor

New York City NEW YORK US

Employees: 70

LUCD Company Website

LUCD Investor Relations

Phone: 12129494319

LUCID DIAGNOSTICS INC / LUCD FAQ

What is the stock price of LUCID DIAGNOSTICS INC today?

The current stock price of LUCD is 1.12 USD. The price decreased by -1.75% in the last trading session.


What is the ticker symbol for LUCID DIAGNOSTICS INC stock?

The exchange symbol of LUCID DIAGNOSTICS INC is LUCD and it is listed on the Nasdaq exchange.


On which exchange is LUCD stock listed?

LUCD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LUCID DIAGNOSTICS INC stock?

12 analysts have analysed LUCD and the average price target is 3.87 USD. This implies a price increase of 245.32% is expected in the next year compared to the current price of 1.12. Check the LUCID DIAGNOSTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LUCID DIAGNOSTICS INC worth?

LUCID DIAGNOSTICS INC (LUCD) has a market capitalization of 121.17M USD. This makes LUCD a Micro Cap stock.


How many employees does LUCID DIAGNOSTICS INC have?

LUCID DIAGNOSTICS INC (LUCD) currently has 70 employees.


What are the support and resistance levels for LUCID DIAGNOSTICS INC (LUCD) stock?

LUCID DIAGNOSTICS INC (LUCD) has a support level at 1.05 and a resistance level at 1.12. Check the full technical report for a detailed analysis of LUCD support and resistance levels.


Is LUCID DIAGNOSTICS INC (LUCD) expected to grow?

The Revenue of LUCID DIAGNOSTICS INC (LUCD) is expected to grow by 39.76% in the next year. Check the estimates tab for more information on the LUCD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LUCID DIAGNOSTICS INC (LUCD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LUCID DIAGNOSTICS INC (LUCD) stock pay dividends?

LUCD does not pay a dividend.


When does LUCID DIAGNOSTICS INC (LUCD) report earnings?

LUCID DIAGNOSTICS INC (LUCD) will report earnings on 2025-08-11, before the market open.


What is the Price/Earnings (PE) ratio of LUCID DIAGNOSTICS INC (LUCD)?

LUCID DIAGNOSTICS INC (LUCD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).


What is the Short Interest ratio of LUCID DIAGNOSTICS INC (LUCD) stock?

The outstanding short interest for LUCID DIAGNOSTICS INC (LUCD) is 6.85% of its float. Check the ownership tab for more information on the LUCD short interest.


LUCD Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to LUCD. When comparing the yearly performance of all stocks, LUCD turns out to be only a medium performer in the overall market: it outperformed 65.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LUCD Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to LUCD. Both the profitability and financial health of LUCD have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LUCD Financial Highlights

Over the last trailing twelve months LUCD reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 3.28% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -216.3%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-30%
Sales Q2Q%-17.28%
EPS 1Y (TTM)3.28%
Revenue 1Y (TTM)39.99%

LUCD Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to LUCD. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of 26.34% and a revenue growth 39.76% for LUCD


Ownership
Inst Owners9.78%
Ins Owners5.61%
Short Float %6.85%
Short Ratio3.76
Analysts
Analysts83.33
Price Target3.87 (245.54%)
EPS Next Y26.34%
Revenue Next Year39.76%